STEMCELL Technologies Inc. Obtains License from iPS Academia Japan for Induced Pluripotent Stem Cell Technologies
News May 02, 2013
The iPS cell technologies developed by iPS Academia Japan are the result of the groundbreaking research of Professor Shinya Yamanaka of the Center for iPS Cell Research and Application (CiRA) at the University of Kyoto, Japan. iPS cells hold immense potential for drug development and disease modeling. Patient-derived cells can be reprogrammed using iPS cell technology and subsequently differentiated into specific cell types of diverse lineages. This enables researchers to develop patient-specific cell lines for, among other applications, screening potential treatments. The personalized nature of this approach ensures greater predictive accuracy in terms of disease modeling and treatment outcome.
Dr. Allen Eaves, President and CEO of STEMCELL Technologies, commented: “STEMCELL Technologies’ goal is to help researchers by providing the best culture media for the derivation, maintenance and differentiation of both iPS cells and ES cells, thereby facilitating the development of clinical applications in tissue engineering and regenerative medicine”.
This agreement will ensure that STEMCELL Technologies continues to offer the most complete, defined system of integrated tools for human pluripotent stem cell research. These include mTeSR™1, the most widely published feeder-free cell culture medium for human embryonic stem cells (ES cells) and iPS cells, and TeSR™-E8™, a low-protein medium containing only the essential 8 ingredients for the culture of ES cells and iPS cells. The STEMdiff™ product line features robust reagents and protocols to reliably differentiate human pluripotent stem cells to various lineages. These high-quality defined reagents for pluripotent cell culture increase experimental reproducibility, eliminate variable biological elements in the culture media and increase the clinical relevance of ES cell and iPS cell research.
3-D Packaging of DNA Regulates Cell IdentityNews
A new study suggests that the ability of a stem cell to differentiate into cardiac muscle (and by extension other cell types) depends on what portions of the genome are available for activation, which is controlled by the location of DNA in a cell’s nucleus.READ MORE
Some 30,000 Biomedical Publications Report on Misidentified CellsNews
Researchers from Radboud University have found more than 30,000 publications are reporting on the wrong cells.